

TABLE OF CONTENTS

FROM THE EDITOR

Postinfectious immunologic syndromes 447

Activation of the immune system can be associated with many off-target manifestations.

Brian F. Mandell, MD, PhD

THE CLINICAL PICTURE

Iatrogenic calcinosis cutis from calcium gluconate extravasation 454

While receiving an infusion of 10% calcium gluconate, the patient developed pain, swelling, and erythema at the catheter site.

Fotios Vlahos, MS; Iosifina Giannakikou, MD

THE CLINICAL PICTURE

Mucocutaneous rash after respiratory infection 457

The patient presented with conjunctivitis, skin rash, and oral and genital mucosal lesions 2 weeks after being ill with a fever, productive cough, and myalgia.

Mandlin Abdulaziz Almousa, DMD; Narath Carlile, MD, MPH; Nathaniel Treister, DMD, DMSc

1-MINUTE CONSULT

When should I order the serum free light-chain assay, and how should I interpret mild kappa or lambda elevations? 459

Reserve the test for scenarios where a plasma cell disorder is clinically suspected, and interpret mild elevations through the lenses of the kappa:lambda ratio and patient context.

Malvinder S. Parmar, MB, MS


1-MINUTE CONSULT

When is brain MRI with and without contrast indicated for evaluation of headache? 463

Secondary headache disorders such as neoplasm or infection are more often suspected than detected, but neuroimaging is warranted when red-flag features are present.

Nicholas Joseph Abdallah, DO; Madisen Olson, DO, MBA

MEDICAL GRAND ROUNDS



Winning the battle against Barrett esophagus and esophageal adenocarcinoma 467

Current efforts are focused on better identifying patients at high risk for Barrett esophagus as candidates for endoscopic screening and developing less invasive and cheaper detection methods.

David A. Katzka, MD

CONTINUED ON PAGE 446

CONTINUED FROM PAGE 439

REVIEW

CME MOC

Navigating pulmonary nodules: Guidelines on assessing risk and determining next steps in primary care 475

The authors offer practical guidance on identifying pulmonary nodules that require surveillance, determining appropriate follow-up intervals, and deciding when specialist evaluation and intervention are needed.

Noah Gordon, DO; Raisa Munshi, MD; Mae Leef, DO; Axel W. Joob, MD; Abdul Hamid Alraiyes, MD

EDITORIAL

Pulmonary nodule management—patients first, guidelines second 485

How we communicate nodule findings to our patients can influence their perception and whether they agree with and adhere to recommendations.

Louis S. H. Lam, MD

REVIEW

Kratom at a crossroads: Trends, controversies, and the evidence gap 487

Amid the opioid crisis, kratom use has grown for self-management of pain, mood symptoms, and opioid withdrawal.

Vania Modesto-Lowe, MD, MPH; Deanna Sgambato, DMS, MHS, PA-C; Jasleen Kaur, MD; Margaret Chaplin, MD

EDITORIAL

An emergency physician's opinion on kratom confusion 493

There is much confusion about who is using kratom, what the drug does, and what we physicians should do about it.

John R. Queen, MD

LETTERS TO THE EDITOR

Letter: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification 451

Abigail Martinez, MD; Hector Bolivar, MD; Marco A. Ruiz, MD

In Reply: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification 451

Ohad Oren, MD, MPH; Abhay Singh, MD; Hetty E. Carraway, MD, MBA; Luke J. Laffin, MD; Steven E. Nissen, MD

Letter: Olanzapine in Parkinson disease and dementia with Lewy bodies 452

Enmanuel A. Leiva-Murillo, MD; Jazmín Olmedo-Alvariza, MD

In Reply: Olanzapine in Parkinson disease and dementia with Lewy bodies 453

Emily Hao, MD; Tamara Lhungay, MD; Jessica Arabi, PharmD, BCCCP; Colin J. Harrington, MD; Iva Neupane, MD

DEPARTMENTS

CME Calendar 449**CME/MOC Instructions 496**